FilingReader Intelligence
Challenger becomes substantial holder in Telix Pharmaceuticals
August 25, 2025 at 10:09 AM UTC•By FilingReader AI
Challenger Limited has become a substantial holder in Telix Pharmaceuticals, acquiring a 5.12% voting stake worth 17,311,650 ordinary shares.
The acquisition involved a mix of on-market and off-market transactions conducted over several months from April to August 2025, reflecting a strategic investment approach by the institutional investor.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
ASX:TLX•Australian Securities Exchange
News Alerts
Get instant email alerts when Telix Pharmaceuticals Limited publishes news
Free account required • Unsubscribe anytime